

# **Institutional Review Board**

## **Tianjin Medical University Cancer Institute and Hospital**

---

### **Notification of Review by Institutional Review Board**

Document Number: E2011070

**Project Summary:**

**Title of project:** A MULTI-CENTER INTERNATIONAL HOSPITAL-BASED CASE-CONTROL STUDY OF LYMPHOMA IN ASIA (AsiaLymph)

**Principle Investigator:** Chen Kexin

**Sponsor of project:** US National Cancer Institute (NCI)

**Review Result:**

The IRB has carefully reviewed the relevant contents of the above research project (see attachment) on Nov. 24, 2011. The IRB approved the protocol of “A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)” and certified that the listed document in attachment 1 could be used in the process of conducting the research.

**Voting Record:**

**Voting people in total: 7; Agreed voting: 7; Agreed voting after review comments were responded and revised: 0; Disagreed voting: 0.**

**The applicants/investigators are required to attach attention on the following:**

- 1. Show fully respect to the respondents and their own willingness, ensure their participant is totally voluntary under full understanding.**
- 2. Stick to the protocol. Report IRB any serious adverse events and unexpected events which may impact the risk and benefits of the study during the research.**
- 3. If the study is longer than 1 year, an annual report should be submitted to the IRB. And a summary report should be submitted at the end of the study to the IRB.**

**Signature of chairman of the IRB or authority**

**(Seal of the IRB)**

**IRB of Tianjin Medical University Cancer Institute and Hospital**

**Nov. 24, 2011**